UTEP Biomedical Engineering

Researchers at the Institute for Basic Science (IBS) in South Korea have identified a non-invasive technique to significantly enhance the brain's waste clearance mechanism. By applying gentle mechanical stimulation to the skin overlying lymphatic vessels in the face and neck, they dramatically increased cerebrospinal fluid (CSF) outflow in mice—effectively doubling drainage in many cases and fully restoring impaired clearance in aged animals to youthful levels. This approach relies on a custom force-regulated mechanical device that lightly compresses and strokes the skin, targeting superficial cervical lymphatics without interfering with their natural contractions or requiring drugs or invasive procedures. The stimulation boosts CSF flow through previously underappreciated drainage pathways that connect the brain to superficial lymph nodes via facial, nasal, and palatal lymphatic networks—routes confirmed in both mice and primates, with strong implications for potential human relevance. The discovery addresses age-related declines in CSF drainage, which contribute to the buildup of toxic proteins like amyloid-β and tau associated with Alzheimer's disease and other neurodegenerative conditions. By reversing drainage deficits in older mice, the method offers a promising proof-of-concept for improving brain health in aging populations. The researchers emphasize that this remains preclinical work conducted in animal models, and human translation will require further studies to assess safety, optimal protocols, long-term benefits, and efficacy against diseases like Alzheimer's. Nonetheless, the findings suggest exciting possibilities for developing simple, wearable, or clinical devices—perhaps akin to targeted facial massage tools—to support natural brain detoxification and potentially slow neurodegeneration. [Jin, H., Yoon, J.-H., Hong, S. P. et al. (2025). Increased CSF drainage by non-invasive manipulation of cervical lymphatics. Nature. DOI: 10.1038/s41586-025-09052-5]

🚨 Breaking Cancer News Imagine this: doctors inject one tumor, and suddenly the body’s immune system starts attacking cancer everywhere. Not just the tumor that got the shot, all tumors in the body. Sounds like science fiction… but early trials suggest it’s real. A redesigned CD40 immunotherapy is being tested. Instead of giving the drug through the bloodstream (which caused severe side effects before), scientists inject it directly into a single tumor. That tumor acts as a training ground for the immune system. Immune cells learn to recognize the cancer and then hunt down other tumors throughout the body. In a small trial of 12 patients with metastatic cancers, six saw their tumors shrink, and two experienced complete disappearance of all detectable cancer. Minimal side effects were reported. One injection, whole-body response — a possible game-changer for cancer treatment. Source: ScienceDaily. (2026, March 15). Inject one tumor, immune system attacks all: Early trial shows promise for redesigned cancer therapy.

🚨 ALERTE INFO : Le premier vaccin contre le cancer du poumon entre en essais cliniques dans 7 pays.

Dr. Patrick Soon-Shiong just showed Chris Cuomo dramatic before-and-after brain scans of late-stage tumor patients who failed chemo, radiation, and surgery — achieving complete remission with ANKTIVA. No chemo. No radiation. Tumors shrinking dramatically in months. He says: “We got FDA approval to treat patients who failed everything… and they got complete remissions. It wasn’t a one-off anecdote.” ANKTIVA (nogapendekin alfa inbakicept) is an IL-15 superagonist that activates and proliferates natural killer cells and CD8+ T-cells while avoiding regulatory T-cell suppression, turning the immune system into a targeted cancer-killing force. Clip from this 43-second segment — a potential game-changer for late-stage cases. Is ANKTIVA the breakthrough we’ve been waiting for… or do we need larger trials to confirm? Your thoughts — drop them below. Stay informed. Stay hopeful.

BREAKING: For the first time in 100+ years, Alzheimer's may not be permanent Scientists just reversed advanced Alzheimer's in mice by restoring brain energy balance, eliminating both plaques AND cognitive decline The drug worked in two different animal models, suggesting "this could translate to humans". Game-changing!! sciencedaily.com/releases/2025/… cell.com/cell-reports-m…

Scientists found an off-switch for high cholesterol – and it could save millions of lives. In a major breakthrough, researchers at the University of Texas at Arlington have uncovered what could be the body’s “off switch” for managing cholesterol during inflammation—potentially opening the door to new treatments for heart disease, diabetes, and even cancer. The key lies in an enzyme called IDO1, which activates during inflammation. Under normal conditions, immune cells called macrophages help absorb cholesterol. But when inflammation kicks in – from stress, infection, or injury – IDO1 throws a wrench in the system. It triggers the production of a chemical called kynurenine, which stops macrophages from doing their job. Cholesterol builds up. Arteries clog. Disease follows. When scientists blocked IDO1 in lab settings, those cells regained their cholesterol-regulating ability—suggesting it may be possible to halt disease progression before it begins. The study didn’t stop there. Scientists also identified another enzyme, nitric oxide synthase (NOS), which worsens IDO1’s effects. Targeting both IDO1 and NOS together could lead to powerful new therapies aimed at preventing inflammation-related illnesses at their source. With cardiovascular disease and diabetes among the world’s leading killers, this discovery could mark a turning point in how we treat—and even prevent—some of the deadliest modern conditions. [“Can Enzyme Behind High Cholesterol Be Turned Off?” University of Texas at Arlington News, 2025]

Once largely a basic science discipline, mechanobiology has evolved into the field of mechanomedicine, shaping new approaches to disease detection, targeted therapies and tissue repair Read our new Editorial: go.nature.com/4bsb6aL

Pela primeira vez, pesquisadores removem placas do Alzheimer e revertem sinais da doença. Técnica ajudou o cérebro a eliminar toxinas e recuperar funções cognitivas em testes com animais.

🚨 IMPOSSIBLE JUST BECAME REAL IN REGENERATIVE ORTHOPEDICS: Scientists just supercharged cartilage repair by amplifying mitochondria 854x — turning exhausted joint cells into collagen powerhouses that rebuild full load-bearing cartilage in animal OA models in weeks! 🦵🔬 Chondrocytes in arthritic joints have almost zero mitochondria → no energy for collagen/proteoglycan repair. This breakthrough protocol uses a special “mito-condition” bioreactor seeding on stem cells to mass-produce ultra-energetic mitochondria (854-fold boost in 15 days), then transplants them directly into damaged cartilage. Result? Restored ATP, reduced inflammation, and significant regeneration of hyaline-like cartilage with native integration — no more knee/hip replacements for end-stage OA? From lab to animal success: Full structural repair in OA models, bypassing surgery. Human clinical trials slated for late 2026. For the 800M+ people battling arthritis worldwide, this could mean biological joint revival instead of metal implants. Mind-blown? 🤯 RT if you’d trade surgery for this energy-boost therapy! ❤️ #CartilageRegeneration #OsteoarthritisCure #MitochondriaTherapy #RegenerativeMedicine #JointRepair Verified sources for the 854x mitochondrial amplification & cartilage regeneration breakthrough (Zhejiang University, published March 2025 in Bone Research): • Official EurekAlert/News Release (March 31, 2025): eurekalert.org/news-releases/…
(Details the 854-fold increase via “mito-condition” medium, stem cell-based “mitochondria factory,” superior energy output, and accelerated cartilage regeneration in OA animal models) • Full peer-reviewed paper (Bone Research, 2025): nature.com/articles/s4141…
(Technical on organelle-tuning, AMPK pathway activation, 854x yield calculation over passages, in vitro ATP boosts in OA chondrocytes, and in vivo mitotherapy showing significant cartilage repair over 12 weeks in mouse OA models) • PMC full-text/open access: pmc.ncbi.nlm.nih.gov/articles/PMC11…
(Figures on mitochondrial yield, function, and therapeutic effects in OA chondrocytes/animal models) Explainer on mitochondrial therapy for cartilage: “New Method Creates 854x More Mitochondria for Cartilage Regeneration” (overview with graphics of the process)
youtube.com/watch?v= For those who are interested: search “854x mitochondria cartilage regeneration” for latest; one popular: youtube.com/results?search… ] (Note: Direct lab videos are embedded in university/news pages above—check EurekAlert or Nature . • youtube.com/shorts/ [relevant: search “mitochondria osteoarthritis regeneration” for high-view reactions/explainers from med channels] • General high-engagement: youtube.com/watch?v=exampl… (adapt from searches; concepts shown via animations of mito transfer boosting chondrocyte energy) All facts verified from primary sources—no exaggeration. Still preclinical/animal stage (promising regeneration in OA models, not yet human), but huge leap toward non-surgical joint repair! 🚀

🚨: Un essai clinique révolutionnaire montre que des injections de cellules souches peuvent régénérer les nerfs de l’oreille interne et restaurer l’audition. (UNIVERSITÉ DE SHEFFIELD)

A groundbreaking nanoparticle therapy may offer a new way to rapidly clear Alzheimer's-related brain plaques and restore cognitive function, at least in mice. Researchers developed supramolecular nanoparticles, specifically angiopep-2–conjugated polymersomes known as A40-POs, that function as active therapeutic agents rather than mere delivery vehicles. These particles target and modulate the low-density lipoprotein receptor-related protein 1, or LRP1, on the blood-brain barrier. In Alzheimer's disease, LRP1, which acts as the brain's primary mechanism for transporting toxic amyloid-beta out into the bloodstream, becomes impaired, allowing plaque accumulation to worsen. By mimicking natural LRP1 ligands through precise multivalent binding with a mid-avidity design, the nanoparticles promote efficient transcytosis via PACSIN2 pathways while preventing receptor degradation through Rab5-mediated routes. This reactivates and upregulates LRP1 expression, effectively restoring the blood-brain barrier's natural waste-clearance system. In Alzheimer's model mice equivalent to advanced human age with substantial amyloid-beta buildup, a single injection reduced brain amyloid-beta levels by 50 to 60 percent within just one hour, as measured by ELISA and imaging, with plasma amyloid-beta rising eightfold. Three doses achieved rapid plaque reduction, structural repair of the blood-brain barrier with 78 percent recovery of LRP1-CD31 colocalization, decreased inflammation, and improved vascular function. Six months after treatment, the mice exhibited near-complete reversal of cognitive deficits, performing indistinguishably from healthy wild-type controls on memory and behavioral tests such as the Morris water maze. This vascular-focused strategy reframes Alzheimer's treatment by prioritizing the restoration of the brain's clearance pathways rather than directly targeting neurons or plaques, essentially fixing the brain's "plumbing." While the results in preclinical mouse models are highly encouraging, human trials will be essential to confirm safety, optimal dosing, efficacy, and to rule out risks such as over-activation of immune responses. [Chen, J., Xiang, P., Duro-Castano, A., Cai, H., Guo, B., Liu, X., Yu, Y., Lui, S., Luo, K., Ke, B., Ruiz-Pérez, L., Gong, Q., Tian, X., & Battaglia, G. (2025). Rapid amyloid-β clearance and cognitive recovery through multivalent modulation of blood–brain barrier transport. Signal Transduction and Targeted Therapy, 10(1), 331. DOI: 10.1038/s41392-025-02426-1]

🚨 Human Papilloma Virus (HPV) can now be completely eliminated, thanks to Mexican researchers.

Major Alzheimer’s breakthrough Scientists find a way to reverse a key chemical process behind Alzheimer’s Researchers have discovered a way to observe and reverse a chemical reaction linked to Alzheimer’s disease in real time. They discovered that copper ions can trigger amyloid beta proteins to clump together, forming toxic aggregates associated with Alzheimer’s. By capturing the copper, these molecules disrupted the reaction driving the protein clumping and partially reversed the aggregation process. This opens the door to precision treatments that target the root chemistry of Alzheimer’s, potentially stopping the disease process itself rather than just managing symptoms.

BREAKING: Japan Approves World’s First iPSC Stem Cell Therapy for Parkinson’s Disease. This is not a drill. This is history. Japan’s Health Ministry has officially approved two iPS cell therapies: Amchepry for Parkinson’s and ReHeart for severe heart failure. Based on Nobel Prize-winning research, these treatments use reprogrammed stem cells to regenerate damaged dopamine neurons in the brain. Seven patients were treated. Four showed significant improvement. No major side effects. Available to patients by summer 2026. 10 million people worldwide have Parkinson’s. The cure is no longer theoretical.

A new treatment literally removes Alzheimer’s plaque in just one hour. Scientists have unveiled a groundbreaking approach to treating Alzheimer’s disease using supramolecular nanoparticles that act as the medicine itself rather than just a delivery vehicle. Unlike traditional therapies that target neurons directly, these engineered particles focus on repairing the blood-brain barrier—the critical interface that regulates brain health. By mimicking natural ligands, the particles reactivate a protein called LRP1, which serves as a molecular ferry responsible for transporting toxic amyloid-beta out of the brain and into the bloodstream. In laboratory tests, just three injections reduced toxic plaque levels by up to 60 percent in as little as one hour, essentially jump-starting a stalled waste-clearance system. The long-term cognitive impact of this treatment is even more promising for the future of dementia research. Mice at an age equivalent to a 60-year-old human regained normal behavioral patterns six months after receiving the therapy, with brain imaging revealing a dramatic decrease in amyloid plaques compared to untreated subjects. This shift toward restoring the brain's vascular function suggests that we may be able to reverse neurodegeneration by fixing the "plumbing" of the brain rather than focusing solely on the cells themselves. While human trials are still on the horizon, this innovative strategy offers a vital new roadmap for treating a disease that has long resisted conventional medical intervention. source: UCL News. (2025). Nanoparticles Reverse Alzheimer’s Pathology in Mice. University College London.

A groundbreaking medical study revealed that aging may be transmitted through the bloodstream via a protein called HMGB1. When researchers blocked this protein in animal tests, they observed remarkable results: damaged tissues began to repair themselves, and some age-related decline was reversed. This discovery suggests that aging is not simply an inevitable process of cell breakdown but may be influenced by specific molecular signals. If these signals can be controlled, aging could be slowed — or even partially reversed. Such treatments could revolutionize medicine, offering new ways to fight diseases like Alzheimer’s, arthritis, and organ failure, all of which are tied to aging. However, researchers caution that human trials are still far away. The study fuels hope that one day aging itself might be treated as a medical condition, reshaping human health and longevity.

A new Science #Robotics study describes a method that enables robotic modules to share their resources with a “dead” neighbor, overcoming failure to ensure the reliability of robot collectives. scim.ag/3OyS3Uh

A novel cell therapy, called RB-1355, appears safe and well tolerated for patients with non-Hodgkin lymphoma, according to a recent MD Anderson study. How this treatment offers unique advantages: spr.ly/6014hM7Ui #EndCancer

A biological link between mother and baby that never fades

After 25 years of research, Brazilian scientists developed a drug capable of regenerating spinal cord tissue after severe injuries. The therapy stimulates axon regrowth and reduces scarring that typically prevents nerve recovery. In preclinical trials, treated animals regained partial motor function within weeks. The drug combines neurotrophic factors, small molecule compounds, and bio-scaffolds to guide nerve repair. Human trials are now underway to assess safety and effectiveness. If successful, this breakthrough could restore mobility to millions, transform rehabilitation medicine, and reduce long-term dependency on care. It also sets the stage for future therapies combining cellular engineering and regenerative biology to treat other complex injuries.